Huatai-PB CSI SH-HK-SZ Brand Name Drug Industry ETF (517120.SS) Price

The ISIN of Huatai-PB CSI SH-HK-SZ Brand Name Drug Industry ETF is CNE100004V42.

The total expense ratio of Huatai-PB CSI SH-HK-SZ Brand Name Drug Industry ETF is 0.60%, which means that investors pay 60.00 CNY per 10,000 CNY in investment capital annually.

The ETF is listed in CNY.

European investors may incur additional costs for currency exchange and transaction fees.

No, Huatai-PB CSI SH-HK-SZ Brand Name Drug Industry ETF does not comply with the EU UCITS investor protection directives.

Huatai-PB CSI SH-HK-SZ Brand Name Drug Industry ETF tracks the performance of the China Securities Shanghai-Hong Kong-Shenzhen Innovative Medicine Industry Index.

Huatai-PB CSI SH-HK-SZ Brand Name Drug Industry ETF is domiciled in CN.

The fund was launched on 7/8/2021.

The Huatai-PB CSI SH-HK-SZ Brand Name Drug Industry ETF mainly invests in Healthcare companies.

The NAV of Huatai-PB CSI SH-HK-SZ Brand Name Drug Industry ETF amounts to 723,605.04 CNY.

Investments can be made through brokers or financial institutions that provide access to trading ETFs.

The ETF is traded on the stock exchange, similar to stocks.

Yes, the ETF can be held in a regular securities account.

The ETF is suitable for both short-term and long-term investment strategies, depending on the investor's goals.

The ETF is valued on a daily stock exchange basis.

Information on dividends should be requested from the provider's website or your broker.

The risks include market fluctuations, currency risks, and the risk associated with smaller companies.

The ETF is obligated to report regularly and transparently on its investments.

The performance can be viewed on Eulerpool or directly on the provider's website.

Further information can be found on the official website of the provider.